Loading clinical trials...

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) | Clinical Trials | Clareo Health

TERMINATEDPHASE4

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation

NCT02837783•Ironwood Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient meets protocol criteria for diagnosis of IBS-C, abdominal pain, abdominal bloating and abdominal girth

Exclusion Criteria

•Patient has history of loose or watery stools
•Patient has both clinically significant findings and unexplained clinically significant alarm symptoms
•Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain
•Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

Locations (1)

Peter Whorwell

Wythenshawe, Manchester, United Kingdom

Key Dates

Start Date

December 21, 2016

Primary Completion Date

October 31, 2018

Completion Date

October 31, 2018

Last Updated

December 6, 2021

Enrollment

ACTUAL participants

Conditions

Irritable Bowel Syndrome Characterized by Constipation

Interventions

Linaclotide

DRUG

Placebo

DRUG

Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

NCT03687814

Irritable Bowel Syndrome Characterized by Constipation

View study

COMPLETEDPHASE3

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT02387359

Irritable Bowel Syndrome Characterized by Constipation

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 6, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions